ArticleERJ open research2026

Long-term impact of elexacaftor/tezacaftor/ivacaftor on small and large airways in people with cystic fibrosis aged ≥6 years: 24-month real-world evidence from the German Cystic Fibrosis Registry.

Stefanie Dillenhöfer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.